3038:TSEKobe Bussan Co., Ltd. Analysis
Data as of 2026-03-15 - not real-time
₩3,450.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
DongKook Life Science is trading near its 20‑day SMA (≈3,568) and 50‑day SMA (≈3,545), with the price (3,450) just above the identified support level of 3,260 and well below the resistance of 3,970. Technical momentum is mixed: the 14‑day RSI sits around 46, indicating no clear overbought or oversold condition, while the MACD shows a bearish divergence (MACD line below signal). Fundamentally, the company faces challenges – revenue has contracted by roughly 9%, free cash flow is deeply negative, and debt‑to‑equity is high at over 29, yet the price‑to‑sales ratio of 0.84 suggests the market may be undervaluing the business relative to peers.
Given the low beta (≈0.17) the stock is less sensitive to market swings, but its 30‑day volatility exceeds 50%, and a historical max drawdown of nearly 39% underscores significant price swings. With no dividend and limited analyst coverage, investors must weigh the undervalued pricing against the operational and liquidity headwinds.
Given the low beta (≈0.17) the stock is less sensitive to market swings, but its 30‑day volatility exceeds 50%, and a historical max drawdown of nearly 39% underscores significant price swings. With no dividend and limited analyst coverage, investors must weigh the undervalued pricing against the operational and liquidity headwinds.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price hovering just above support with limited upside to resistance
- Bearish MACD signal suggesting further downside risk
- Decreasing volume indicating waning short‑term buying interest
Medium Term
1–3 yearsNeutral
Model confidence: 4/10
Key Factors
- Negative revenue growth and negative free cash flow pressuring earnings
- High debt load relative to equity increasing financial risk
- Potential upside if the market re‑prices the low price‑to‑sales multiple
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Undervalued valuation metrics (low P/S) may attract value‑oriented investors
- Diversified product portfolio across APIs, diagnostics, and imaging equipment
- Long‑run recovery possible if the company improves cash generation and reduces leverage
Key Metrics & Analysis
Financial Health
Revenue Growth-9.20%
Profit Margin5.13%
ROE5.68%
ROA4.03%
Debt/Equity29.32
Op. Cash Flow₩2.0B
Free Cash Flow₩-7722277888
Industry P/E26.2
Technical Analysis
TrendNeutral
RSI45.9
Support₩3,260.00
Resistance₩3,970.00
MA 20₩3,568.25
MA 50₩3,544.90
MA 200₩4,064.70
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta0.17
Volatility54.60%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.